Molecular imaging medical device company Positron has announced the launch of the NeuSight PET-CT 3D 64 slice scanner in the US and North American markets.
Manufactured by Neusoft Medical Systems, the system is designed to enhance imaging and diagnostic precision, patient comfort, and operational efficiency for hospitals and nuclear cardiology practices.
Positron holds exclusive rights to sell and distribute the scanner in North America through an agreement with Shenyang Intelligent Nuclear Medical Technology, a subsidiary of Neusoft Medical Systems.
With installations worldwide, the NeuSight PET-CT scanner has superior data acquisition and identification technology, enhancing scanning speed and accuracy.
Detector modules of the scanner have been designed to interface with scintillating crystals, improving photoelectric conversion efficiency, sensitivity, and temporal resolution.
Its IPIE technology further enhances spatial resolution and accuracy of data.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe scanner’s clear honeycomb and asymmetrical light-guided technology offer better image resolution and clarity, which are essential for accurate cardiac diagnostics.
It also features 72cm gantry and high-sensitivity acquisition technology for safety with minimal exposure to radiation.
Positron president Adel Abdullah said: “We are excited to bring the NeuSight PET-CT to imaging practices and hospitals serving both segment of nuclear cardiology and oncology imaging.
“NeuSight PET-CT is a versatile scanner and an ideal solution for SPECT providers adopting the PET modality. NeuSight PET-CT is also a great fit for oncology practices seeking new systems for enhanced diagnostic and disease management capabilities.
“The NeuSight PET-CT system has been extremely successful for Neusoft Medical Systems with approximately 500 systems sold internationally, and we are confident we will see similar demand in the United States and all of North America.”